L
Laurie H. Sehn
Researcher at University of British Columbia
Publications - 380
Citations - 17159
Laurie H. Sehn is an academic researcher from University of British Columbia. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Rituximab. The author has an hindex of 54, co-authored 310 publications receiving 13190 citations. Previous affiliations of Laurie H. Sehn include BC Cancer Research Centre & BC Cancer Agency.
Papers
More filters
Journal ArticleDOI
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Laurie H. Sehn,Brian R. Berry,Mukesh Chhanabhai,Catherine Fitzgerald,Karamjit Gill,Paul Hoskins,Richard Klasa,Kerry J. Savage,Tamara Shenkier,Judy Sutherland,Randy D. Gascoyne,Joseph M. Connors +11 more
TL;DR: A retrospective analysis of patients with DLBCL treated with R-CHOP to assess the value of the IPI in the era of immunochemotherapy found it to be a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials.
Journal ArticleDOI
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson,Graham W. Slack,Kerry J. Savage,Joseph M. Connors,Susana Ben-Neriah,Sanja Rogic,David W. Scott,King Tan,Christian Steidl,Laurie H. Sehn,Wing C. Chan,Javeed Iqbal,Paul N. Meyer,Georg Lenz,George E. Wright,Lisa M. Rimsza,Carlo Valentino,Patrick Brunhoeber,Thomas M. Grogan,Rita M. Braziel,James R. Cook,Raymond R. Tubbs,Dennis D. Weisenburger,Elias Campo,Andreas Rosenwald,German Ott,German Ott,Jan Delabie,Christina Holcroft,Elaine S. Jaffe,Louis M. Staudt,Randy D. Gascoyne +31 more
TL;DR: Assessment of MYC and BCL2 expression by IHC represents a robust, rapid, and inexpensive approach to risk-stratify patients with DLBCL at diagnosis.
Journal ArticleDOI
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou,Laurie H. Sehn,Alfred Rademaker,Leo I. Gordon,Ann S. LaCasce,Allison Crosby-Thompson,Ann Vanderplas,Andrew D. Zelenetz,Gregory A. Abel,Maria Alma Rodriguez,Auayporn Nademanee,Mark S. Kaminski,Myron S. Czuczman,Michael Millenson,Joyce C. Niland,Randy D. Gascoyne,Joseph M. Connors,Jonathan W. Friedberg,Jane N. Winter +18 more
TL;DR: The NCCN-IPI is easy to apply and more powerful than the IPI for predicting survival in the rituximab era and demonstrated enhanced discrimination for both low- and high-risk patients.
Journal ArticleDOI
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
Kerry J. Savage,Nathalie A. Johnson,Susana Ben-Neriah,Joseph M. Connors,Laurie H. Sehn,Pedro Farinha,Douglas E. Horsman,Randy D. Gascoyne +7 more
TL;DR: The diagnosis of MYC+ DLBCL is likely underappreciated; and given the lack of defining risk factors, fluorescence in situ hybridization for MYC rearrangements should be performed in all patients withDLBCL.
Journal ArticleDOI
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore,Vindi Jurinovic,Robert Kridel,Eva Hoster,Annette M. Staiger,Annette M. Staiger,Monika Szczepanowski,Christiane Pott,Nadja Kopp,Mark A. Murakami,Heike Horn,Heike Horn,Ellen Leich,Alden A. Moccia,Anja Mottok,Ashwini Sunkavalli,Paul Van Hummelen,Matthew D. Ducar,Daisuke Ennishi,Hennady P. Shulha,Christoffer Hother,Joseph M. Connors,Laurie H. Sehn,Martin Dreyling,Donna Neuberg,Peter Möller,Alfred C. Feller,Martin L. Hansmann,Harald Stein,Andreas Rosenwald,German Ott,Wolfram Klapper,Michael Unterhalt,Wolfgang Hiddemann,Randy D. Gascoyne,David M. Weinstock,Oliver Weigert +36 more
TL;DR: This work aimed to improve risk stratification of patients receiving first-line immunochemotherapy by integrating gene mutations into a prognostic model by establishing a clinicogenetic risk model that included the Follicular Lymphoma International Prognostic Index (FLIPI) and Eastern Cooperative Oncology Group (ECOG) performance status.